Delphi Management Inc. MA lowered its stake in shares of Roche Holdings AG Basel ADR (OTCMKTS:RHHBY) by 3.4% during the second quarter, Holdings Channel reports. The fund owned 66,985 shares of the company’s stock after selling 2,371 shares during the period. Delphi Management Inc. MA’s holdings in Roche Holdings AG Basel were worth $2,054,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Ferguson Wellman Capital Management Inc. boosted its stake in shares of Roche Holdings AG Basel by 3.0% in the 2nd quarter. Ferguson Wellman Capital Management Inc. now owns 313,772 shares of the company’s stock valued at $8,670,000 after purchasing an additional 9,025 shares during the last quarter. Chartwell Investment Partners LLC bought a new position in shares of Roche Holdings AG Basel in the 2nd quarter valued at about $743,000. Todd Asset Management LLC boosted its stake in shares of Roche Holdings AG Basel by 2.3% in the 2nd quarter. Todd Asset Management LLC now owns 118,900 shares of the company’s stock valued at $3,285,000 after purchasing an additional 2,700 shares during the last quarter. Pillar Pacific Capital Management LLC boosted its stake in shares of Roche Holdings AG Basel by 3.8% in the 2nd quarter. Pillar Pacific Capital Management LLC now owns 154,118 shares of the company’s stock valued at $4,279,000 after purchasing an additional 5,635 shares during the last quarter. Finally, Boston Common Asset Management LLC boosted its stake in shares of Roche Holdings AG Basel by 28.7% in the 2nd quarter. Boston Common Asset Management LLC now owns 497,686 shares of the company’s stock valued at $13,818,000 after purchasing an additional 110,858 shares during the last quarter. 0.57% of the stock is currently owned by hedge funds and other institutional investors.

Several research analysts have recently issued reports on the stock. Zacks Investment Research raised shares of Roche Holdings AG Basel from a “hold” rating to a “strong-buy” rating and set a $35.00 target price on the stock in a research note on Wednesday, September 12th. Bank of America lowered shares of Roche Holdings AG Basel from a “buy” rating to a “neutral” rating in a research note on Monday, September 10th. ValuEngine raised shares of Roche Holdings AG Basel from a “sell” rating to a “hold” rating in a research note on Thursday, August 30th. Cowen reissued a “buy” rating and set a $34.00 price objective on shares of Roche Holdings AG Basel in a research note on Thursday, July 26th. Finally, Credit Suisse Group reissued an “underperform” rating on shares of Roche Holdings AG Basel in a research note on Friday, May 25th. Four investment analysts have rated the stock with a sell rating, five have given a hold rating, three have issued a buy rating and one has issued a strong buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $34.50.

Roche Holdings AG Basel stock opened at $30.68 on Tuesday. Roche Holdings AG Basel ADR has a fifty-two week low of $26.30 and a fifty-two week high of $32.42. The company has a market cap of $210.19 billion, a P/E ratio of 15.73, a PEG ratio of 1.87 and a beta of 0.65. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.09 and a current ratio of 1.42.

Roche Holdings AG Basel Company Profile

Roche Holding AG diagnostics and pharmaceuticals businesses in Switzerland, Germany, and rest of Europe. It offers pharmaceutical products for anaemia, anticoagulation therapy, bone, cancer, cardiovascular, central nervous system, chlamydia, coagulation, dermatology, diabetes, gonorrhea, gout, hemostasis disorders, hepatitis B and C, HIV/AIDS, HPV, infectious diseases, inflammatory and autoimmune, intensive care medicine, kidney and urogenital tract, leukemia, lipid disorders, liver, lymphoma, metabolic disorders, obesity, occult blood testing, ophthalmology, osteoporosis, pancreatitis, respiratory disorders, rheumatoid arthritis, sepsis, sexually transmitted infections, skin cancer, transplantation, tuberculosis, urinary tract infections, and West Nile virus diseases.

Recommended Story: How to Invest in Growth Stocks

Want to see what other hedge funds are holding RHHBY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Roche Holdings AG Basel ADR (OTCMKTS:RHHBY).

Institutional Ownership by Quarter for Roche Holdings AG Basel (OTCMKTS:RHHBY)

Receive News & Ratings for Roche Holdings AG Basel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche Holdings AG Basel and related companies with MarketBeat.com's FREE daily email newsletter.